Replies to post #233238 on Avid Bioservices Inc (CDMO)

[BioBS2012]

So did we throw a ton of cash toward phase 3 that has no relevancy on the comparator arm? Hence the large share request and start up of new NSCLC trial.

As stated previously it all depends on where the SUNRISE data ends up. I believe it needs to hit the 60% improvement at the very least over docetaxel. Everything we know thus far would seem to suggest it should do that, and more :-). Now we wait for the results. Until then it is a matter of patience. I am inclined to be very patient with my PPHM investment.

Cheers.